The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia
Abstract
Purpose: The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alfa given with IV iron versus with local standard practice (oral iron or no iron). Patients and Methods: In this multicenter, randomized, open-label, phase III study, 396 patients with nonmyeloid malignancies and hemoglobin (Hb) less than 11 g/dL received darbepoetin alfa 500 μg with (n = 200) or without (n = 196) IV iron once every 3 weeks (Q3W) for 16 weeks. Results: The hematopoietic response rate (proportion of patients achieving Hb ≥ 12 g/dL or Hb increase of ≥ 2 g/dL from baseline) was significantly higher in the IV iron group: 86% versus 73% in the standard practice group (difference of 13% [95% CI, 3% to 23%]; P = .011). Fewer RBC transfusions (week 5 to the end of the treatment period) occurred in the IV iron group: 9% versus 20% in the standard practice group (difference of −11% [95% CI, −18% to −3%]; P = .005). Both treatments were well tolerated with no notable differences in adverse events. Serious adverse events related to iron occurred in 3% of patients in the IV iron group and were mostly gastrointestinal in nature. Conclusion: Addition of IV iron to darbepoetin alfa Q3W in patients with chemotherapy-induced anemia was well tolerated, resulting in an improved hematopoietic response rate and lower incidence of transfusions compared with darbepoetin alfa alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Cited by
The Safety of Intravenous Iron Preparations
Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., & Gafter-Gvili, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.007 · Cited by 441
Detection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Litton, E., Xiao, J., & Ho, K. M. (2013) · BMJ · doi:10.1136/bmj.f4822 · Cited by 394
Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2201 · Cited by 303
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx758 · Cited by 288
Metadata
- Authors
- Bastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pintér, T., Suto, T. S., Mossman, T. W., Smith, K. E., & Vansteenkiste, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1611-1618
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170238323
- Cited by
- 195
- References
- 1
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia. https://app.cochat.ai/papers/10.1200/jco.2006.10.4620
- The paper
- Bastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pintér, T., Suto, T. S., Mossman, T. W., Smith, K. E., & Vansteenkiste, J. F. (2008). Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.10.4620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.